Related coverage linked through entity extraction aliases.
Jul 21, 2026
Helus completed Phase 3 enrollment for HLP003 in depression; data due Q4 2026. Compass is on track for COMP360's NDA, and an ayahuasca ingredient showed promise in a phase 2a trial.
Jun 11, 2026
Helus Pharma announced publication in Nature Medicine of Phase 2a trial results showing its short-acting psychedelic SPL026 met its primary endpoint with significant reductions in depressive symptoms at two weeks in moderate-to-severe MDD patients. The company also appointed a new SVP of Medical Affairs and is advancing HLP003 (Breakthrough Therapy Designation from FDA) and HLP004 in its pipeline.
Apr 20, 2026
Compass Pathways reported positive late-stage COMP360 psilocybin data in treatment-resistant depression and plans FDA talks ahead of a filing between October and December. The update lifted shares across several psychedelics developers.
Feb 23, 2026
A phase 2 trial found that a single intravenous dose of dimethyltryptamine (DMT) alongside psychotherapy significantly reduced major depressive disorder symptoms, with effects lasting up to 6 months.
Feb 17, 2026
Compass Pathways reports positive Phase 3 results for synthetic psilocybin in treatment-resistant depression, while a Phase 2 trial demonstrates rapid antidepressant effects from single-dose DMT. Both studies show modest efficacy signals amid growing pharmaceutical interest in psychedelic compounds.
